The South African Medical Research Council (SAMRC) has taken a major step forward in the global fight against HIV with the launch of the BRILLIANT 011 first-in-human clinical trial, enrolling its first participant this week at the Desmond Tutu HIV Foundation (DTHF) site at Groote Schuur Hospital. This milestone trial represents a historic achievement in African-led HIV vaccine research and brings renewed optimism for developing a vaccine tailored to the continent’s needs.
The BRILLIANT 011 study is testing two next-generation HIV vaccine components, BG505 GT1.1 and 426c.Mod.Core-C4b administered with the SMNP adjuvant to assess their safety and the immune responses they elicit in humans. These advanced immunogens were developed through extensive international collaboration involving the International AIDS Vaccine Initiative, the Fred Hutchinson Cancer Center, the Scripps Consortium for HIV/AIDS Vaccine Development, and the Amsterdam University Medical Centers.
SAMRC sponsor representative Professor Glenda Gray highlighted the importance of the trial for advancing local scientific leadership in vaccine development. “Advances in HIV vaccine research and development place our team in a pivotal position to map immune responses to these novel vaccines in order to guide further development of this regimen,” she said, noting the trial’s potential to inform future vaccine strategies.
The BRILLIANT 011 study is part of the BRILLIANT Consortium (BRinging Innovation to cLinical and Laboratory research to end HIV In Africa through New vaccine Technology), an initiative launched in 2024 to unify leading researchers from South Africa, Nigeria, Uganda, Kenya, Tanzania, Zimbabwe, Zambia and Mozambique. The consortium is notable for being predominantly led by African women scientists, with SAMRC directing the first human study.
Despite facing significant challenges, including U.S. funding cuts that threatened to derail the programme, the consortium demonstrated scientific resilience by mobilising new investment and preserving the research’s integrity, enabling the trial to proceed.
The BRILLIANT 011 trial focuses on whether these cutting-edge vaccine components can safely prime the human immune system and generate responses that could prevent infection or inform future vaccine iterations. Enrolling HIV-negative volunteers, the study will provide early clinical insights into immune activation and safety, laying the groundwork for subsequent trials and vaccine platforms.
The launch of this trial reinforces Africa’s growing role in leading biomedical research, especially in areas that disproportionately affect the continent. By coordinating across multiple African nations and institutions, the BRILLIANT Consortium is not only advancing scientific knowledge but also building clinical research capacity, fostering collaborations and enhancing the region’s ability to respond to future health challenges.
Photo courtesy / Medpagetoday
Article by Jed Mwangi
Comment